Latest News — Page 9

The RECOVER-VITAL trial found nirmatrelvir-ritonavir offered no benefit for long COVID across cognitive, autonomic, or exercise symptoms. The study also shows why placebo controls matter: a large share of the placebo group improved on their own. #SyenzaNews #LongCOVID #ClinicalTrials #MarketAccess

FDA has authorized Stryker SportSuite Vision, the first surgical application built for Apple Vision Pro. The De Novo clearance is narrow: hip arthroscopy display, used alongside standard monitors. #SyenzaNews #DigitalHealth #MedTech #FDA #AppleVisionPro

EMA scientific advice volumes hit a record in the first half of 2026. The agency is planning pre-payment at submission, an agile advice pilot for 2027, and a regulatory sandbox workshop in September. #SyenzaNews #EMA #MarketAccess #DrugDevelopment

Novartis’ oral BTK inhibitor remibrutinib met its primary endpoint in the Phase III REMODEL-1 and REMODEL-2 trials, cutting annualized relapse rates versus teriflunomide in relapsing multiple sclerosis. #SyenzaNews #MultipleSclerosis #MarketAccess #Neurology

Portuguese private health insurers cleared €1 billion in six months as premiums climbed 9.1% to €466 a year. #SyenzaNews #HealthInsurance #Portugal #MarketAccess

The United States has added nine more manufacturers to its most-favored-nation drug pricing program, taking the total to 26 companies that now cover 89% of the branded drug market. #MarketAccess #DrugPricing #Pharma

Cipla has licensed Sino Biopharm’s HER2 biparatopic ADC TQB2102 for India, South Africa and five other emerging markets. The deal caps at USD 123 million plus double-digit royalties, with access to HER2-low breast cancer as the core case. #SyenzaNews #Oncology #MarketAccess #DrugDevelopment

Insurers are spending billions on breakthrough medicines, but the tests that decide who gets them are still an afterthought. Kathryn Phillips lays out four reforms to link drug and diagnostic policy pathways. #SyenzaNews #diagnostics #healtheconomics #MarketAccess

A new benchmark in npj Digital Medicine finds frontier AI models at near-perfect accuracy on German medical licensing exams, yet image questions still cut their scores far more than for students. #SyenzaNews #AIinHealthcare #DigitalHealth

South Africa is preparing to register and introduce a new tuberculosis vaccine if late-stage Phase 3 trials succeed. Cabinet confirmed the plans this week and welcomed a Serum Institute of India agreement to manufacture TB vaccines for global distribution.
#SyenzaNews #globalhealth #clinicaltrials #MarketAccess

The Fifth Circuit affirmed the constitutionality of the Medicare drug price negotiation program, rejecting claims from NICA, the Global Colon Cancer Association, and PhRMA. #SyenzaNews #DrugPricing #MarketAccess #Pharma

Finland, UNRISD and the WHO asked what the Economics of Health for All strategy means for the next generation, from intergenerational fairness and participatory foresight to dignified access to care. #SyenzaNews #HealthEconomics #WellbeingEconomy

France reimbursed 90% of drug costs in 2024, yet many patients still feel shortchanged. Maurice-Pierre Planel breaks down the numbers behind the paradox. #SyenzaNews #MarketAccess #PharmaPolicy

In Alberta, patients of fee-for-service heart specialists receive roughly three times the cardiac testing, with no measurable difference in outcomes. #HealthEconomics #PhysicianPayment #SyenzaNews

A real-world study from Eli Lilly finds sustained Zepbound use lowers healthcare costs in adults over 55, with savings exceeding the Medicare GLP-1 Bridge price within 12 months. #SyenzaNews #MarketAccess #Obesity #HealthEconomics

EMA has authorised Ablymico, a synthetic liraglutide for weight management. The approval, granted on 15 July 2026, covers adults, adolescents and children from age six. Ablymico is bioequivalent to Saxenda but is produced by chemical synthesis rather than living cells. #SyenzaNews #MarketAccess #Obesity #GLP1